Long before the advent of Coronavirus, next-generation therapies were making headlines, but the successful development of COVID-19 vaccines, including mRNA vaccines, has now shone a spotlight on next-generation therapies. This offers a boost to the long-term growth projections for the advanced therapy medicinal products (ATMPs) sector. But although ATMPs hold…
List view / Grid view
Astellas and Dyno Therapeutics will develop adeno-associated virus (AAV) vectors for gene therapy directed to skeletal and cardiac muscle.
This whitepaper considers sterility testing to support pharmacopeial monographs with an emphasis on products that are difficult to test or validate.
29 November 2021 | By
This whitepaper provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly.
This whitepaper explores drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.
This webinar considers the fundamental importance of water system control within pharma processing and the best control and monitoring practices.
This whitepaper explores vaccine development during a pandemic, a response to complex challenges that traditional manufacturing methods won’t solve.
The Gates Biomanufacturing Facility announced a strategic agreement with Nkarta to manufacture Nkarta's investigational cell therapy NKX101.
The consortium also consists of 10 pharmaceutical companies and five organisations to accelerate gene therapies to treat rare diseases.
RoslinCT and Connect 2 Cleanrooms have worked in partnership to deliver a world-class cell and gene therapy facility.
18 October 2021 | By 908Devices
In this on-demand webinar, 908 Devices present a microfluidic capillary zone electrophoresis-based separation coupled with HRAM mass-spectrometry for rapid characterisation of oligos in positive ionisation mode.
Researchers show combining mass spectrometry and a gas-phase electrophoretic mobility molecular analyser improves detection of full and empty virus-like particles for gene therapies.
The European Federation of Pharmaceutical Industries will implement a new regulation to co-ordinate genetically modified organism procedures.